Trade Report: Today: Regeneron Pharmaceuticals Inc. (REGN) is Premier Asset Managment LLC’s 5th Largest Position

Today: Regeneron Pharmaceuticals Inc. (REGN) is Premier Asset Managment LLC’s 5th Largest Position

Premier Asset Managment LLC cut its position in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 4.7% during the third quarter, Holdings Channel reports. The fund owned 34,840 shares of the biopharmaceutical company’s stock after selling 1,735 shares during the period. Regeneron Pharmaceuticals makes up approximately 3.5% of Premier Asset Managment LLC’s portfolio, making the stock its 5th largest position. Premier Asset Managment LLC’s holdings in Regeneron Pharmaceuticals were worth $14,006,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in REGN. IFP Advisors Inc raised its position in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares in the last quarter. Advisory Services Network LLC raised its position in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 326 shares in the last quarter. Fuller & Thaler Asset Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $140,000. Brave Asset Management Inc bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $157,000. Finally, CIBC World Markets Inc. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $202,000. Institutional investors own 68.26% of the company’s stock.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 1.77% on Monday, hitting $391.13. 521,852 shares of the stock were exchanged. The company has a 50-day moving average of $381.52 and a 200 day moving average of $389.29. The firm has a market cap of $41.00 billion, a P/E ratio of 57.07 and a beta of 1.79. Regeneron Pharmaceuticals Inc. has a 12 month low of $325.35 and a 12 month high of $566.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.73 by $0.40. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.29 billion. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The company’s revenue was up 7.3% on a year-over-year basis. During the same period last year, the firm earned $3.47 EPS. Equities research analysts expect that Regeneron Pharmaceuticals Inc. will post $11.73 earnings per share for the current fiscal year.

Several research analysts recently issued reports on the company. Vetr raised Regeneron Pharmaceuticals to a “buy” rating in a research report on Monday, November 21st. BTIG Research reaffirmed a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 17th. Jefferies Group reaffirmed a “hold” rating and set a $394.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 17th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $412.00 target price for the company in a research report on Wednesday, November 9th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $379.00 target price (down from $448.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, November 7th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $468.87.

In related news, Director Arthur F. Ryan sold 2,000 shares of the firm’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total transaction of $858,680.00. Following the completion of the transaction, the director now directly owns 36,500 shares of the company’s stock, valued at $15,670,910. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph L. Goldstein sold 2,125 shares of the firm’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $450.00, for a total transaction of $956,250.00. Following the transaction, the director now directly owns 15,125 shares of the company’s stock, valued at $6,806,250. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Related posts

Leave a Comment